东阳光(600673) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,715,013,192.43, representing a decrease of 4.48% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥65,642,499.06, down 77.20% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥88,173,060.12, a decrease of 71.57% compared to the previous year[4]. - The basic earnings per share were ¥0.022, down 77.78% year-on-year[4]. - Net profit for Q1 2023 was ¥63,257,618.65, a significant decline of 78.83% compared to ¥299,717,956.37 in Q1 2022[20]. - Earnings per share (EPS) for Q1 2023 was ¥0.022, down from ¥0.099 in Q1 2022[20]. Cash Flow - The net cash flow from operating activities was ¥158,184,276.76, reflecting a decline of 73.00% year-on-year[4]. - In Q1 2023, the cash inflow from operating activities was approximately ¥2.41 billion, a decrease of 28.1% compared to ¥3.36 billion in Q1 2022[21]. - The net cash flow from operating activities was ¥158.18 million, down 73.0% from ¥585.85 million in the same period last year[21]. - The net cash flow from investing activities was ¥26.04 million, a significant improvement from a negative cash flow of ¥774.25 million in Q1 2022[22]. - Cash inflow from financing activities totaled approximately ¥2.74 billion, an increase of 15.1% compared to ¥2.38 billion in Q1 2022[22]. - The net cash flow from financing activities was ¥33.81 million, recovering from a negative cash flow of ¥240.79 million in the previous year[22]. - The ending balance of cash and cash equivalents was approximately ¥3.58 billion, up from ¥1.65 billion at the end of Q1 2022[22]. - The company received cash from investment recovery of ¥300 million, down from ¥380 million in Q1 2022[21]. - Cash paid for purchasing fixed assets was ¥282.15 million, a decrease of 59.1% from ¥690.54 million in the same period last year[22]. - The cash received from other financing activities was approximately ¥812.32 million, compared to ¥1.03 billion in Q1 2022[22]. - The cash outflow for other investment activities was ¥26.51 million, slightly down from ¥30.44 million in the previous year[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥24,474,175,162.86, a slight decrease of 0.06% from the end of the previous year[5]. - Total liabilities amounted to ¥13,732,748,016.48, a decrease of 4.00% from ¥14,306,134,240.85 in the previous year[18]. - Total equity attributable to shareholders reached ¥10,313,969,087.53, an increase of 5.75% from ¥9,753,083,721.37 in Q1 2022[18]. - Current assets totaled CNY 11,059,281,690.26, down from CNY 11,331,697,726.28 at the end of 2022, indicating a decrease of approximately 2.4%[16]. - Total assets as of March 31, 2023, amounted to CNY 24,474,175,162.86, a slight decrease from CNY 24,488,202,600.72 at the end of 2022[14]. - Total amount of accounts payable decreased to ¥1,327,930,078.14 from ¥1,668,261,030.53, reflecting a reduction of 20.43%[17]. - Non-current liabilities totaled ¥3,334,058,573.36, an increase of 30.00% from ¥2,568,331,049.83 in Q1 2022[18]. Investments and Shareholder Information - The company recorded a significant increase in investment income by 340.63% due to improved capital efficiency[9]. - Major shareholders include Shenzhen Dongyangguang Industrial Development Co., Ltd. with a 25.98% stake and Yichang Dongyangguang Pharmaceutical Co., Ltd. with an 18.08% stake[12]. - The company reported an investment income of ¥38,070,631.79, significantly higher than ¥8,640,142.52 in the same quarter last year[20]. - The company reported a total of 62,411 common shareholders at the end of the reporting period[12]. Operating Costs and Expenses - Total operating costs increased to ¥2,710,136,609.59, up 10.19% from ¥2,459,519,420.52 in the same period last year[19]. - Research and development expenses for Q1 2023 were ¥86,947,532.79, down 17.16% from ¥105,080,640.05 in Q1 2022[19].